Cite

HARVARD Citation

    Kassner, U. et al. (2019). Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies (Pcsk9-I) Treatment Of Cardiovascular High Risk Patients In Clinical Practice. Atherosclerosis. pp. e212-. [Online]. 
  
Back to record